GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Equity-to-Asset

Eidos Therapeutics (Eidos Therapeutics) Equity-to-Asset : 0.76 (As of Sep. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Eidos Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $122.86 Mil. Eidos Therapeutics's Total Assets for the quarter that ended in Sep. 2020 was $161.35 Mil. Therefore, Eidos Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2020 was 0.76.

The historical rank and industry rank for Eidos Therapeutics's Equity-to-Asset or its related term are showing as below:

EIDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.08   Med: 0.84   Max: 0.97
Current: 0.76

During the past 4 years, the highest Equity to Asset Ratio of Eidos Therapeutics was 0.97. The lowest was -2.08. And the median was 0.84.

EIDX's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.66 vs EIDX: 0.76

Eidos Therapeutics Equity-to-Asset Historical Data

The historical data trend for Eidos Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Equity-to-Asset Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Equity-to-Asset
-1.25 -2.08 0.97 0.84

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.84 0.84 0.80 0.76

Competitive Comparison of Eidos Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Eidos Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eidos Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Equity-to-Asset falls into.



Eidos Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Eidos Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Equity to Asset (A: Dec. 2019 )=Total Stockholders Equity/Total Assets
=171.427/203.82
=0.84

Eidos Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2020 is calculated as

Equity to Asset (Q: Sep. 2020 )=Total Stockholders Equity/Total Assets
=122.856/161.351
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eidos Therapeutics  (NAS:EIDX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Eidos Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Eidos Therapeutics (Eidos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Executives
Uma Sinha director, officer: Chief Scientific Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle officer: Senior Vice President, Finance 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle officer: Chief Business Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox officer: See Remarks C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen director 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat director, 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu officer: CFO and Secretary C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc. 10 percent owner 421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar director, 10 percent owner, officer: Chief Executive Officer C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Eidos Therapeutics (Eidos Therapeutics) Headlines

From GuruFocus